BetterLife Pharma adds Sergei Stetsenko to its board of directors to prepare for its growth phase in psychedelic medicines

BetterLife Pharma Inc. (CSE:BETR) (OTCQB:BETRF) (FRA:NPAU) announced that it has added Sergei Stetsenko to its board of directors to prepare for its growth phase in psychedelic medicines.  The emerging biotech company noted that Stetsenko is a financier and venture capitalist who is acting chief executive officer of CRG Finance AG, a private venture capital firm in Zurich, Switzerland.  As lead investor of CRG Finance, he has helped acquire, build and exit businesses via public markets and raising capital for companies in the technology, healthcare, communications and natural resources sectors.   Stetsenko is also currently the chief executive officer of BlockchainK2 Corp., a publicly-listed company investing in blockchain technology solutions for capital markets and other sectors that can benefit from tokenization. READ: BetterLife Pharma adds psychedelic industry leaders to its senior management team following recent takeover of Transcend Biodynamics BetterLife Pharma also announced that it has retained the services of ROK Consulting, Inc. for investor relations and marketing activities over a 2-month term for a fee of US$200,000 and the issuance of 300,000 common shares. The common shares will be issued at the end of the agreement term and will be subject to resale restrictions pursuant to applicable securities laws and the policies of the Canadian Securities Exchange. The emerging biotechnology company is engaged in the development and commercialization of therapeutic pharmaceuticals as well as drug delivery platform technologies. BetterLife is refining and developing drug candidates from a broad set of complementary interferon-based technologies which have the potential to engage the immune system to fight virus infections, such as the coronavirus disease (COVID-19) and human papillomavirus (HPV), and/or to directly inhibit tumours to treat specific types of cancer. Contact the author at jon.hopkins@proactiveinvestors.com